Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Queensland Health
Teva
Express Scripts
Citi
Johnson and Johnson
Accenture

Generated: May 24, 2018

DrugPatentWatch Database Preview

XOLEGEL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Xolegel, and what generic alternatives are available?

Xolegel is a drug marketed by Aqua Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-eight patent family members in fifteen countries.

The generic ingredient in XOLEGEL is ketoconazole. There are fifteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the ketoconazole profile page.
Summary for XOLEGEL
International Patents:28
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 61
Patent Applications: 4,505
Formulation / Manufacturing:see details
DailyMed Link:XOLEGEL at DailyMed
Drug patent expirations by year for XOLEGEL
Medical Subject Heading (MeSH) Categories for XOLEGEL
Synonyms for XOLEGEL
(+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine
(+)-Ketoconazole
(+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine
(+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine
(2R,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
(2R,4S)-ketoconazole
1-(4-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethan-1-one
1-(4-(4-(((2R,4S)-2-((1H-IMIDAZOL-1-YL)METHYL)-2-(2,4-DICHLOROPHENYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)ETHANONE
1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one
1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
142128-59-4
24F2-1,25(OH)D3
277K421
65277-42-1
AB0090681
AB02344
AC-15957
AC1L9UG3
AKOS007930650
API0003081
BDBM60666
BDBM8610
BIDD:GT0696
BIM-0050645.0001
BPBio1_000635
BRD-K29113274-001-03-6
BRN 4303081
BSPBio_000577
C26H28Cl2N4O4
CAS-65277-42-1
CCG-100815
CHEBI:48336
CHEMBL75
CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE
cis-1-Acetyl-4-[4-[[2-(2,4-
cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy]phenyl]piperazine
cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine
CPD000058460
CS-1846
dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine
DRG-0073
DSSTox_CID_9879
DSSTox_GSID_29879
DSSTox_RID_78829
DTXSID7029879
EI-107
EINECS 265-667-4
EU-0100666
Extina
Fungarest
Fungoral
HMS1569M19
HMS2051A19
HMS2089N05
HMS2096M19
HMS2234H17
HMS3262E13
HSDB 7447
HY-B0105A
J10202
K 1003
K0045
KCZ
Ketocanazole
Ketoconazol
ketoconazole
Ketoconazole (k)
Ketoconazole [USAN:INN:BAN:JAN]
Ketoconazole 2.0 mg/ml in Methanol
Ketoconazole, >=98% (HPLC)
Ketoconazole, Antibiotic for Culture Media Use Only
Ketoconazole, British Pharmacopoeia (BP) Reference Standard
Ketoconazole, European Pharmacopoeia (EP) Reference Standard
Ketoconazole, pharmaceutical secondary standard; traceable to USP and PhEur
Ketoconazole, United States Pharmacopeia (USP) Reference Standard
Ketoconazolum
Ketoderm
Ketoisdin
KS-1205
KTN
KTZ
Kuric
KZ
Lopac0_000666
LP00666
LS-110149
MCULE-2726394491
MFCD00058579
MLS000069784
MLS000758224
MLS001146934
MLS001423987
MLS002207053
MLS002222255
MolPort-003-848-307
MRF-0000100
NC00065
NCGC00016907-01
NCGC00025000-01
NCGC00025000-02
NCGC00025000-03
NCGC00025000-04
NCGC00025000-05
NCGC00025000-06
NCGC00025000-07
NCGC00025000-08
NCGC00025000-09
NCGC00025000-10
NCGC00253967-01
NCGC00261351-01
Nizoral
NSC 317629
Opera_ID_397
Piperazine, (+)-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-
Piperazine, (+/-)-1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel-
Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis-
Prestwick_744
Prestwick0_000389
Prestwick1_000389
Prestwick2_000389
Prestwick3_000389
Q-201267
R 41,400
R-41400
R41,400
R41400
rac-trans-Ketoconazole
s1353
SAM001246983
SCHEMBL8407
SMR000058460
SPBio_002498
SR-01000075626
SR-01000075626-1
SR-01000597381
SR-01000597381-6
ST2407064
Tocris-1103
Tox21_110676
Tox21_300267
Tox21_500666
UNII-R9400W927I component XMAYWYJOQHXEEK-OZXSUGGESA-N
UPCMLD-DP138
UPCMLD-DP138:001
US9150527, Ketoconazole
W-2941
ZINC643138

US Patents and Regulatory Information for XOLEGEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for XOLEGEL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,238,683 Anhydrous topical skin preparations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Federal Trade Commission
QuintilesIMS
US Department of Justice
Express Scripts
Johnson and Johnson
UBS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.